Translate the text from Welsh to English.



 
Pwyllgor cynghori arbenigol annibynnol yw’r Cyd\-bwyllgor ar Imiwneiddio a Brechu (JCVI). Mae’n cynghori adrannau iechyd y Deyrnas Unedig ynghylch imiwneiddio, gan wneud argymhellion am amserlenni brechu a diogelwch brechlynnau.


Heddiw, mae’r JCVI wedi cyhoeddi datganiad yn cynnwys ei gyngor diweddaraf ar frechiadau Covid\-19 ar gyfer plant rhwng chwe mis a phedair blwydd oed (dolen allanol, Saesneg yn unig).


Er bod lefel uchel o imiwnedd cryf wedi datblygu yn y boblogaeth dros y ddwy flynedd a hanner diwethaf, mae’r risg o salwch difrifol yn sgil Covid\-19 yn parhau i fod yn anghymesur o uchel ar gyfer pobl mewn grwpiau oedran hŷn; preswylwyr cartrefi gofal ar gyfer oedolion hŷn, a phobl â chyflyrau iechyd sy’n bodoli eisoes. Mae ansicrwydd yn parhau o ran a fydd y feirws yn esblygu ac yn newid ac, os felly, sut; pa mor hir y bydd imiwnedd yn para, ac epidemioleg heintiau.


Ar 6 Rhagfyr 2022, cymeradwyodd yr Asiantaeth Rheoleiddio Meddyginiaethau a Chynhyrchion Gofal Iechyd (MHRA) y brechlyn COVID\-19 Pfizer\-BioNTech ar gyfer plant rhwng chwe mis a phedair blwydd oed. Mae’r JCVI wedi cwrdd i adolygu data diweddar sy’n gysylltiedig â threialon brechlynnau pediatrig Covid\-19; gwyliadwriaeth diogelwch brechlynnau pediatrig Covid\-19 yn yr Unol Daleithiau, ac epidemioleg Covid\-19 yn y DU mewn plant rhwng chwe mis a phedair blwydd oed.


Wrth lunio’r cyngor yn ymwneud ag imiwneiddio plant, mae’r JCVI wedi nodi’n gyson y dylid canolbwyntio ar y manteision a’r niweidiau posibl sy’n gysylltiedig â brechu i blant a phobl ifanc eu hunain, gan sicrhau mai atal plant a phobl ifanc rhag cael Covid\-19 difrifol (mynd i’r ysbyty a marwolaethau) yw’r prif nod. Drwy gydol y pandemig, mae astudiaethau wedi dangos bod plant yn llawer llai tebygol o gael Covid\-19 difrifol o gymharu ag oedolion. Ar gyfer y rhan fwyaf o blant, caiff haint SARS\-CoV\-2 ei gysylltu â symptomau ysgafn, neu dim symptomau o gwbl.


Fodd bynnag, ar gyfer cyfran lai o blant â chyflyrau iechyd sy’n bodoli eisoes, mae’r risg o salwch difrifol yn uwch. Mae’r tebygolrwydd o fynd i unedau gofal dwys pediatrig gyda Covid\-19 difrifol dros saith gwaith yn fwy ar gyfer babanod a phlant ifanc â chyflyrau meddygol sy’n bodoli eisoes, o gymharu â phlant eraill.


Felly, cyngor y JCVI yw:


Ar gyfer plant rhwng chwe mis a phedair blwydd oed sydd mewn grŵp risg clinigol (fel y’i diffinnir yn y Llyfr Gwyrdd), dylid cynnig dau ddos 3\-microgram o frechlyn COVID\-19 Pfizer\-BioNTech (Comirnaty®) gyda chyfnod o o leiaf wyth wythnos rhwng y dos cyntaf a’r ail ddos. Dylid aros o leiaf pedair wythnos ar ôl cael haint SARS\-CoV\-2 diweddar, cyn cael dos o’r brechlyn.


Mae GIG Cymru wedi bod yn ystyried trefniadau ar gyfer brechu’r grŵp hwn o blant a bydd rhagor o wybodaeth ar gael i rieni plant cymwys. Cânt wahoddiad i ddod am frechiad.


Ochr yn ochr â’m cymheiriaid yn y DU, rwyf wedi derbyn y cyngor hwn, ac rwy’n hynod ddiolchgar i’r GIG ac i bawb sy’n rhan o’r rhaglen frechu am eu gwaith caled parhaus.


Caiff y datganiad ei gyhoeddi yn ystod y toriad er mwyn rhoi'r wybodaeth ddiweddaraf i aelodau. Os bydd aelodau eisiau i mi wneud datganiad pellach neu ateb cwestiynau ynglŷn â hyn pan fydd y Senedd yn dychwelyd, byddwn yn hapus i wneud hynny.







Translation:


 
The Joint Committee on Vaccination and immunisation (JCVI) is an independent expert advisory committee, which advises United Kingdom health departments about immunisation, making recommendations about vaccination schedules and vaccine safety.


The JCVI has today published a statement with its latest advice on COVID\-19 vaccination for children aged six months to four years (external link).


While there is a high level of strong population immunity developed over the past two\-and\-a\-half years, the risk of severe illness from Covid\-19 continues to be disproportionately higher in people in older age groups, residents in care homes for older adults and people with certain underlying health conditions. There also remains ongoing uncertainty about whether or how the virus will evolve and change, how long immunity will last, and the epidemiology of infection.


On 6 December 2022, the Medicines and Healthcare products Regulatory Agency (MHRA) approved the Pfizer BioNTech COVID\-19 vaccine for children aged six months to four years. The JCVI has met to review recent data related to Covid\-19 paediatric vaccine trials, safety surveillance of paediatric Covid\-19 vaccines in the United States, and the epidemiology of Covid\-19 in the UK in children aged six months to four years.


When formulating advice in relation to childhood immunisations, the JCVI has consistently maintained that the focus should be on the potential benefits and harms of vaccination to children and young people themselves, with the prevention of severe Covid\-19 (hospitalisations and deaths) in children and young people the primary aim.Throughout the pandemic, studies have shown that children are much less likely to develop severe Covid\-19 disease than older adults. For the vast majority of children, SARS\-CoV\-2 infection is associated with no, or mild, symptoms.


However, for a smaller proportion of children with pre\-existing health conditions, the risk of severe illness is greater. The odds of admission to paediatric intensive care units with severe Covid\-19 is more than seven times greater for infants and young children with underlying medical conditions compared to children without underlying medical conditions.


Therefore, the JCVI has advisedthat:


Children aged six months to four years in a clinical risk group (as defined in the Green Book) should be offered two 3microgram doses of the Pfizer\-BioNTech COVID\-19 vaccine (Comirnaty®) with an interval of at least eight weeks between the first and second doses. The minimum interval between any vaccine dose and recent SARS\-CoV\-2 infection should be four weeks.


NHS Wales has been considering arrangements for vaccinating this group of children and further information will be made available to parents of eligible children to invite them to come forward for vaccination.


Alongside my UK counterparts, I have accepted this advice and I am extremely grateful to the NHS and everyone involved in the vaccination programme for their continued hard work.


This statement is being issued during recess in order to keep members informed. Should members wish me to make a further statement or to answer questions on this when the Senedd returns I would be happy to do so*.*